By Marie Rosenthal
The FDA approved glycopyrrolate inhalation solution (Lonhala Magnair, Sunovion) for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Glycopyrrolate inhalation solution is the first nebulized, long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the United States and the first use of the Magnair, which is based on the closed eFlow